A pyroptosis-related lncRNA risk model for the prediction of prognosis and immunotherapy response in head and neck squamous cell carcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identifies two pyroptosis subtypes in head and neck squamous cell carcinoma (HNSC) and develops a six long non-coding RNA (lncRNA) risk model. This model predicts patient survival and response to immunotherapy, offering new therapeutic strategies.
Area Of Science
- Oncology
- Molecular Biology
- Immunology
Background
- Pyroptosis is increasingly recognized as a critical factor in cancer progression.
- Understanding pyroptosis-related signatures is crucial for predicting outcomes in head and neck squamous cell carcinoma (HNSC).
Purpose Of The Study
- To investigate the association between pyroptosis signatures and overall survival (OS) in HNSC.
- To develop a pyroptosis-related long non-coding RNA (lncRNA) risk model for prognosis and immunotherapy response prediction in HNSC.
Main Methods
- Utilized Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) datasets for HNSC expression data.
- Performed consensus clustering to identify pyroptosis-related subtypes.
- Constructed a six-lncRNA risk score model using Cox regression analyses and validated with RT-qPCR and IHC.
Main Results
- Identified two distinct pyroptosis-related subtypes (Cluster A and B), with Cluster B showing significantly poorer OS.
- Developed a six-lncRNA risk score model that effectively stratified patients into high- and low-risk groups with differential OS.
- The risk model correlated with immunotherapy response, indicating better outcomes for the low-risk group receiving immune checkpoint blockade (ICB) therapy.
Conclusions
- Pyroptosis signatures play a significant role in HNSC prognosis.
- The developed six-lncRNA risk model is a valuable tool for predicting HNSC patient prognosis and response to ICB therapy.
- Findings emphasize the importance of pyroptosis and lncRNAs in the HNSC tumor microenvironment, suggesting potential for targeted therapies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...